MoFo News Item

MoFo Represents Everest Medicines II in VenatoRx Partnership

28 Sep 2018

Morrison & Foerster is representing Everest Medicines II Limited, a C-Bridge Capital-backed biopharmaceutical company, in its exclusive collaboration, license and supply agreement with VenatoRx Pharmaceuticals, Inc., to support the development, registration and commercialization of cefepime/VNRX-5133 in parts of Asia.

VenatoRx is a world leader in antibacterial and antiviral drug research and development. Under the agreement, Everest and VenatoRx will collaborate on the global Phase 3 clinical development trials of cefepime/VNRX-5133, an injectable broad-spectrum beta-lactamase inhibitor, with Everest obtaining the exclusive right to develop and commercialize it in Greater China, South Korea and Southeast Asia. VenatoRx will receive up to US$114 million in upfront and milestone payments and additional running royalties.

This partnership closely follows another major collaboration and licensing arrangement that MoFo completed on behalf of C-Bridge Capital and Everest Medicines Limited. In December 2017, MoFo advised on the partnership with Arena Pharmaceuticals for $212 million in upfront and milestone payments to develop and commercialize ralinepag and etrasimod in Mainland China, Taiwan, Hong Kong, Macau, and South Korea.

The MoFo team is led by Hong Kong partner Chuan Sun, with support from associate Alex Cao.



Unsolicited e-mails and information sent to Morrison & Foerster will not be considered confidential, may be disclosed to others pursuant to our Privacy Policy, may not receive a response, and do not create an attorney-client relationship with Morrison & Foerster. If you are not already a client of Morrison & Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.